详情页 - 河北大学附属医院知识库

资源类型：

文章类型：

作者：

Shi, Yuankai[1,2,3] * ; Chen, Gongyan[4] ; Wang, Xiang[5] ; Liu, Yunpeng[6] ; Wu, Lin[7] ; Hao, Yanrong[9] ; Liu, Chunling[10] ; Zhu, Shuyang[11] ; Zhang, Xiaodong[12] ; Li, Yuping[13] ; Liu, Jiwei[14] ; Cao, Lejie[15] ; Cheng, Ying[16] ; Zhao, Hui[17] ; Zhang, Shucai[18] ; Zang, Aimin[19]

; Cui, Jiuwei[20] ; Feng, Jian[21] ; Yang, Nong[8] ; Liu, Fei[22] ; Jiang, Yong[22] ; Gu, Chuan[22] ; for the FURLONG investigators[1] ;

机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Med Oncol, Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing 100021, Peoples R China [2]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Beijing 100021, Peoples R China [3]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Beijing 100021, Peoples R China [4]Harbin Med Univ, Dept Med Oncol, Canc Hosp, Harbin, Peoples R China [5]Xuzhou Cent Hosp, Dept Med Oncol, Xuzhou, Jiangsu, Peoples R China [6]China Med Univ, Dept Med Oncol, Hosp 1, Shenyang, Peoples R China [7]Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med,Thorac Med Dept 2, Changsha, Peoples R China [8]Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med,Dept Med Oncol,Lung Canc & Gastro, Changsha, Peoples R China [9]Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Med Oncol, Nanning, Peoples R China [10]Xinjiang Med Univ, Dept Pulm Med, Canc Hosp, Urumqi, Peoples R China [11]Xuzhou Med Coll, Dept Resp Med, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China [12]Nantong Canc Hosp, Dept Med Oncol, Nantong, Peoples R China [13]Wenzhou Med Univ, Dept Resp & Crit Care Med, Affiliated Hosp 1, Wenzhou, Peoples R China [14]Dalian Med Univ, Dept Oncol, Affiliated Hosp 1, Dalian, Peoples R China [15]USTC, Dept Resp Med, Affiliated Hosp 1, Hefei, Peoples R China [16]Jilin Canc Hosp, Dept Oncol, Changchun, Peoples R China [17]Anhui Univ, Dept Resp & Crit Care Med, Hosp 2, Hefei, Peoples R China [18]Capital Med Univ, Beijing Chest Hosp, Beijing TB & Thorac Oncol Inst, Dept Oncol, Beijing, Peoples R China [19]Hebei Univ,Dept Med Oncol,Affiliated Hosp,Baoding,Peoples R China [20]First Hosp Jilin Univ, Canc Ctr, Changchun, Peoples R China [21]Nantong Univ, Dept Resp Med, Affiliated Hosp, Nantong, Peoples R China [22]Shanghai Allist Pharmaceut, Shanghai, Peoples R China

出处：

DOI：

ISSN：

基金：

语种：

高被引：

热点：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 1 区

医学

小类 | 1 区危重病医学 1 区呼吸系统

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区危重病医学 1 区呼吸系统

JCR分区：

出版当年[2022]版：

Q1 CRITICAL CARE MEDICINE Q1 RESPIRATORY SYSTEM

最新[2023]版：

Q1 CRITICAL CARE MEDICINE Q1 RESPIRATORY SYSTEM

第一作者：

第一作者机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Med Oncol, Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing 100021, Peoples R China [2]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Beijing 100021, Peoples R China [3]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Beijing 100021, Peoples R China

通讯作者：

通讯机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Med Oncol, Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing 100021, Peoples R China [2]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Beijing 100021, Peoples R China [3]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Beijing 100021, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study

文献详情

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study $(function () { $("[data-toggle='tooltip']").tooltip(); });

文献详情

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study